Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | POLR1A | O95602 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26723966 | 1.00 | CHRM3 (0.39) | CHRM3NPC1HPGDRAB9APARP1 | |
| SCHEMBL26724468 | 0.99 | CHRM3 (0.38) | CHRM3NPC1HPGDRAB9A | |
| SCHEMBL26724256 | 0.96 | CHRM3 (0.42) | CHRM3 | |
| SCHEMBL26724267 | 0.96 | CHRM3 (0.42) | CHRM3 | |
| SCHEMBL24763646 | 0.90 | CHRM3 (0.34) | CHRM3 | |
| SCHEMBL26724715 | 0.90 | CHRM3 (0.34) | CHRM3 | |
| SCHEMBL26205578 | 0.89 | CHRM3 (0.41) | CHRM3NPC1HPGDRAB9A | |
| SCHEMBL26727407 | 0.89 | CHRM3 (0.41) | CHRM3NPC1HPGDRAB9A | |
| SCHEMBL24763581 | 0.87 | CHRM3 (0.38) | CHRM3NPC1HPGDRAB9A | |
| SCHEMBL26209373 | 0.87 | CHRM3 (0.41) | CHRM3NPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CHRM3 179/4885NPC1 667/4885HPGD 905/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CHRM3 179/4885NPC1 667/4885HPGD 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.